CPT® Code 91307

Deleted

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

The CPT® Code 91307 refers to a specific vaccine designed to provide immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the disease known as coronavirus disease (COVID-19). This vaccine utilizes a formulation of messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), specifically designed to deliver the genetic instructions for producing the spike protein of the virus. The spike protein is a critical component that the virus uses to enter human cells, and by introducing this protein into the body, the vaccine prompts an immune response. The immune system recognizes the spike protein as foreign, leading to the production of antibodies that can neutralize the virus upon future exposure. The vaccine is preservative-free and is administered intramuscularly in a dosage of 10 mcg per 0.2 mL. It is important to note that this particular code is used to report the supply of the Pfizer two-dose pediatric vaccine and booster, specifically for children aged 5 to 11 years, with an additional third dose available for immunocompromised individuals. The preparation of the vaccine involves diluting it with preservative-free normal saline to achieve the correct dosage, distinguishing it from the adult formulation, which is a ready-to-use TRIS/sucrose formulation that includes buffering agents to stabilize the product and maintain pH levels. The actual injection of the vaccine is reported separately using the appropriate administration code, which varies based on the dose administered.